Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1996 Jun;104(3):454–459. doi: 10.1046/j.1365-2249.1996.42748.x

Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome

S BACMAN 1, L STERIN-BORDA 1, J JOSÉ CAMUSSO 1, R ARANA 1, O HUBSCHER 1, E BORDA 1
PMCID: PMC2200439  PMID: 9099930

Abstract

In this study we demonstrate that IgG present in the sera of patients with primary Sjögren's syndrome (PSS) could bind and activate muscarinic acetylcholine receptors (mAChRs) of rat parotid gland. These antibodies were able to inhibit in a non-competitive manner the binding of 3H-quinuclidinyl benzilate (QNB) to mAChRs of purified rat parotid gland membranes. Moreover, IgG from PSS could modify biological effects mediated by mAChR activation; i.e. decrease cAMP, increase phosphoinositide turnover without affecting cGMP. Atropine and 4-DAMP blocked all of these effects, and carbachol mimicked them, confirming the M3 subtype mAChRs mediated PSS IgG action. Neither binding nor biological effect were obtained with IgG from sera of normal women. The prevalence of cholinergic antibody was 100% in PSS, and was independent of Ro/SS-A and La/SS-B antibodies. It could be concluded that antibody against mAChRs may be another serum factor to be considered in the pathophysiology of the development of PSS.

Keywords: parotid gland, M3, muscarinic receptors, antibodies, primary Sjögren's syndrome

Full Text

The Full Text of this article is available as a PDF (351.8 KB).


Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES